|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0033684,
umls-concept:C0039194,
umls-concept:C0086418,
umls-concept:C0871261,
umls-concept:C1425141,
umls-concept:C1515655,
umls-concept:C1517050,
umls-concept:C1533691,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-2-27
|
|
pubmed:abstractText |
Members of the T cell, Ig domain and mucin domain (Tim) family of proteins have recently been implicated in the control of T cell-mediated immune responses. Tim-1 (HUGO designation HAVCR1) polymorphisms have been linked to the regulation of atopy in mice and humans, suggestive of a role in immune regulation. Tim-1 is expressed upon activation of T cells. In concert with the increased expression of Tim-1, a binding partner for the extracellular domain of Tim-1 (eTim-1) was induced on activated T cells, and mRNA expression data was consistent with the binding partner being Tim-4. We found that co-immobilized recombinant eTim-1 was able to inhibit T cell activation mediated by CD3 + CD28 mAb. eTim-1 mediated its inhibitory effects on proliferation by arresting cell cycle at G(0)/G(1) phase through regulation of cell cycle proteins. In vivo, administration of eTim-1 proteins led to a decrease in both ear (contact hypersensitivity to oxazolone) and joint (methylated BSA antigen-induced arthritis) swelling. The inhibitory activity of eTim-1 in the T(h)1-dependent models was evidence that eTim-1 is able to modulate T cell responses. Manipulation of the Tim-1 interaction with its binding partner on T cells may therefore provide a novel target for therapeutic intervention in T cell-mediated diseases.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/HAVCR1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Virus,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/TIM-4 protein, mouse
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0953-8178
|
|
pubmed:author |
pubmed-author:BendeleAlisonA,
pubmed-author:BoldogFerencF,
pubmed-author:BurgessCatherineC,
pubmed-author:ChapovalAndreiA,
pubmed-author:GhatpandeAshwiniA,
pubmed-author:HackettCraigC,
pubmed-author:MolJ CJC,
pubmed-author:PenaCarol ECE,
pubmed-author:ShenoySureshS,
pubmed-author:ShimketsRichard ARA,
pubmed-author:SmithsonGlenndaG,
pubmed-author:StarlingGary CGC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
473-84
|
|
pubmed:dateRevised |
2007-6-20
|
|
pubmed:meshHeading |
pubmed-meshheading:16481347-Animals,
pubmed-meshheading:16481347-Arthritis,
pubmed-meshheading:16481347-CHO Cells,
pubmed-meshheading:16481347-Cell Cycle,
pubmed-meshheading:16481347-Cricetinae,
pubmed-meshheading:16481347-Cricetulus,
pubmed-meshheading:16481347-Dermatitis, Contact,
pubmed-meshheading:16481347-G0 Phase,
pubmed-meshheading:16481347-G1 Phase,
pubmed-meshheading:16481347-Humans,
pubmed-meshheading:16481347-Lymphocyte Activation,
pubmed-meshheading:16481347-Male,
pubmed-meshheading:16481347-Membrane Glycoproteins,
pubmed-meshheading:16481347-Membrane Proteins,
pubmed-meshheading:16481347-Mice,
pubmed-meshheading:16481347-Mice, Inbred BALB C,
pubmed-meshheading:16481347-Receptors, Interleukin-2,
pubmed-meshheading:16481347-Receptors, Virus,
pubmed-meshheading:16481347-Recombinant Fusion Proteins,
pubmed-meshheading:16481347-T-Lymphocytes
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins.
|
|
pubmed:affiliation |
CuraGen Corporation, Branford, CT 06405, USA. info@curagen.com
|
|
pubmed:publicationType |
Journal Article
|
